AI Article Synopsis
- A study was conducted to explore the prognostic significance of ecotropic viral integration site 1 (EVI1) in pediatric acute myeloid leukemia (AML) using data from 421 patients under uniform treatment across seven centers in China.
- EVI1 was detected in 9% of patients, mostly in those with acute megakaryoblastic leukemia and poor cytogenetic profiles, and was linked to significantly worse overall survival (OS) outcomes based on statistical analyses.
- Hematopoietic stem cell transplantation (HSCT) during first complete remission showed potential survival benefits compared to chemotherapy for patients with EVI1, although the results were not yet statistically conclusive.
Article Abstract
Background: A high ecotropic viral integration site 1 ( expression ( ) is an independent prognostic factor in adult acute myeloid leukemia (AML). However, little is known of the prognostic value of in pediatric AML. This study aimed to examine the biological and prognostic significance of in uniformly treated pediatric patients with AML from a large cohort of seven centers in China.
Methods: A diagnostic assay was developed to determine the relative expression using a single real-time quantitative polymerase chain reaction in 421 newly diagnosed pediatric AML patients younger than 14 years from seven centers in southern China. All patients were treated with a uniform protocol, but only 383 patients were evaluated for their treatment response. The survival data were included in the subsequent analysis (n = 35 for , n = 348 for ).
Results: was found in 9.0% of all 421 pediatric patients with AML. was predominantly found in acute megakaryoblastic leukemia (FAB M7), rearrangements, and unfavorable cytogenetic aberrance, whereas it was mutually exclusive with t (8; 21), inv (16)/t (16; 16), , , or mutations. In the univariate Cox regression analysis, had a significantly adverse 5-year event-free survival (EFS) and overall survival (OS) [hazard ratio (HR) = 1.821 and 2.401, = 0.036 and 0.005, respectively]. In the multivariate Cox regression analysis, was an independent prognostic factor for the OS (HR = 2.447, = 0.015) but not EFS (HR = 1.556, p = 0.174). Furthermore, was an independent adverse predictor of the OS and EFS of patients with rearrangements (univariate analysis: HR = 9.921 and 7.253, both < 0.001; multivariate analysis: HR = 7.186 and 7.315, = 0.005 and 0.001, respectively). Hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) provided patients with a tendential survival benefit when compared with chemotherapy as a consolidation (5-year EFS: 68.4% 50.8%, = 0.26; 5-year OS: 65.9% 54.8%, = 0.45).
Conclusion: It could be concluded that can be detected in approximately 10% of pediatric AML cases. It is predominantly present in unfavorable cytogenetic subtypes and predicts adverse outcomes. Whether pediatric patients with AML can benefit from HSCT in CR1 needs to be researched further.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474639 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.712747 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML.
Blood Res
December 2024
Division of Laboratory Hematology and Blood Banking, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Meshkin Fam Street, P.O. Box, Shiraz, 71345-1744, Iran.
Background: Acute myeloid leukemia (AML) is a heterogeneous malignancy that responds to various therapies. The sensitivity of leukemia cells to chemotherapy is affected by the DNA damage response (DDR). In this study, we examined the association between RAD51 rs1801320, XRCC3 rs861539, NBS1 rs1805794, MRE11 rs569143, and RAD50 rs2299014 variants of the homologous recombination repair (HRR) pathway and AML outcomes.
View Article and Find Full Text PDFPopulation pharmacokinetic and exposure-response analysis to support a dosing regimen of CPX-351 (NS-87) in Japanese adult and pediatric patients with untreated high-risk acute myeloid leukemia.
Drug Metab Pharmacokinet
November 2024
Drug Metabolism and Pharmacokinetics Research Department, Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Japan.
CPX-351 (NS-87; Vyxeos®) has a characteristic liposomal formulation and contains cytarabine and daunorubicin at a 5:1 molar ratio, which demonstrates synergistic activity in both in vitro and in vivo animal models. It has been approved in several countries for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Since there are very few Asian patients, especially Japanese adult and pediatric patients, only a small clinical study has been conducted in Japanese adult patients and no study in Japanese pediatric patients.
View Article and Find Full Text PDFThe Therapeutic Potential of Oral Everolimus for Facial Angiofibromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of Efficacy.
Diseases
December 2024
Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, Japan.
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD).
View Article and Find Full Text PDFGenome-wide CRISPR screen identifies AraC-Dauno-Eto (ADE) response modulators that predicts outcome in pediatric AML.
Blood Adv
December 2024
University of Florida, Gainesville, Florida, United States.
Cytarabine, daunorubicin, and etoposide (ADE) have been the standard backbone of induction chemotherapy regimens for acute myeloid leukemia (AML) patients for over five decades. However, chemoresistance is still a major concern, and a significant proportion of AML becomes resistant to ADE treatment leading to relapse and poor survival. Therefore, there is a significant need to identify mechanisms mediating drug resistance to overcome chemoresistance.
View Article and Find Full Text PDFPredictors and Early Treatment of Knee Arthrofibrosis After Arthroscopic Knee Ligament Reconstruction Surgery in Adolescent Patients.
Orthop J Sports Med
December 2024
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Background: Postoperative knee arthrofibrosis after arthroscopic ligament reconstruction is a serious complication. Among adolescents, risk factors for postoperative arthrofibrosis are not well characterized and the effectiveness of early manipulation under anesthesia (MUA) is not well established.
Purposes: To identify risk factors for arthrofibrosis after arthroscopic knee ligament reconstruction in adolescent patients and to evaluate the safety and effectiveness of early MUA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!